Drug intelligence / Profile preview

CIN-108

Development stage: Preclinical
Lead developer: Cinsano Pharma
Modality: Small Molecules

Overview

CIN-108 is a small molecule inhibitor targeting defective in cullin neddylation 1 (DCN1), a protein involved in the neddylation pathway that regulates protein degradation. By inhibiting DCN1 from binding in its necessary pocket, CIN-108 disrupts the neddylation process, which interferes with the progression of multiple solid tumors and cancers. DCN1 is an oncogene amplified in various cancer types and correlates with more severe prognosis. The compound was initially developed by Cinsano Pharma and later licensed by CinRx for further optimization and development as an oncology therapeutic[1][2][3].

Targets

DCUN1D1 (Defective in Cullin neddylation protein 1)

Beyond the preview

Go deeper on CIN-108.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CIN-108.

Explore the full profile